CORDIS
EU research results

CORDIS

English EN

Nucleobase derivatives as drugs against trypanosomal diseases

Project information

Grant agreement ID: 223238

Status

Closed project

  • Start date

    1 January 2009

  • End date

    30 June 2012

Funded under:

FP7-HEALTH

  • Overall budget:

    € 3 542 209,60

  • EU contribution

    € 2 557 187

Coordinated by:

AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS

Spain

Objective

The protozoan diseases, leishmaniasis, African trypanosomiasis and Chagas’ disease are responsible for substantial global morbidity, mortality, and economic adversity, and in most countries, existing strategies for control and treatment are either failing or under serious threat. New tools for combating pathogenic protozoa and the development and exploitation of new drug targets are required. This proposal builds on several achievements and observations of the consortium in the area of nucleotide metabolism. •Pyrimidine and purine metabolism exhibits unique features in trypanosomes. •The identification of a unique enzyme involved in pyrimidine metabolism restricted to trypanosomes and essential for viability: the dimeric all-alpha dUTPase. •An exceptional collection of purine and pyrimidine analogues is available through the consortium for antiprotozoal screening and lead identification. •The consortium brings together an outstanding combination of expertise for drug discovery. The main objective is the identification of new purine and pyrimidine derivatives for the treatment of the leishmaniases and trypanosomiases. A two-pronged approach is proposed to discover new leads for the treatment of leishmaniasis and trypanosomiasis targeting nucleoside/ nucleotide metabolism. 1)The phenotypic approach exploring the potential of large collections of novel nucleobase derivatives against trypanosomal diseases. 2)The target-based approach specifically centred on the development of inhibitors of the enzyme deoxyuridine triphosphate nucleotidohydrolase. The trypanosomal enzyme shows structural and functional characteristics which differ profoundly from the mammalian counterpart. The aim is to identify potent inhibitors that are active against parasitic protozoa, active in rodent models of infection and have drug-like properties.

Coordinator

AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS

Address

Calle Serrano 117
28006 Madrid

Spain

Activity type

Research Organisations

EU Contribution

€ 615 665

Administrative Contact

Alberto Sereno Alvarez (Mr.)

Participants (6)

UNIVERSITY OF DUNDEE

United Kingdom

EU Contribution

€ 508 354

UNIVERSITY OF YORK

United Kingdom

EU Contribution

€ 349 658

SCHWEIZERISCHES TROPEN- UND PUBLIC HEALTH-INSTITUT

Switzerland

EU Contribution

€ 294 312

MEDIVIR AB

Sweden

EU Contribution

€ 229 599

SYNGENE INTERNATIONAL LIMITED PLC

India

EU Contribution

€ 280 200

INSTITUT PASTEUR DE MONTEVIDEO

Uruguay

EU Contribution

€ 279 399

Project information

Grant agreement ID: 223238

Status

Closed project

  • Start date

    1 January 2009

  • End date

    30 June 2012

Funded under:

FP7-HEALTH

  • Overall budget:

    € 3 542 209,60

  • EU contribution

    € 2 557 187

Coordinated by:

AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS

Spain

This project is featured in...